Continuous subcutaneous insulin infusion (CSII) using an insulin pump is an increasingly popular treatment option for children and adults with type 1 diabetes (T1D).1, 2, 3 In meta‐analyses of randomized controlled trials, CSII is associated with improved glycaemic control and lower risk of severe hypoglycaemia compared with multiple daily injection (MDI) therapy.4 CSII aims to mimic the physiological basal and prandial insulin profile, with basal infusion rates set to cover varying requirements during the night and between meals and user‐activated bolus doses at mealtimes. The gene discussed is INS; the disease is Hypoglycemia.